Fly News Breaks for January 5, 2018
UTHR
Jan 5, 2018 | 07:35 EDT
Oppenheimer analyst Hartaj Singh raised his price target for United Therapeutics to $180 saying tax reform is a tailwind for the company. As United returns to sales/earnings growth post the Adcirca patent loss in May 2018, the stock should outperform due to earnings upgrades, Singh tells investors in a research note. He remains bullish on the shares with an Outperform rating.
News For UTHR From the Last 2 Days
There are no results for your query UTHR